Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ICEL

(ICEL) (ICEL) Stock Price, News & Analysis

(ICEL) logo

About (ICEL) Stock (NASDAQ:ICEL)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
264,387 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company's products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.

Remove Ads
Receive ICEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (ICEL) and its competitors with MarketBeat's FREE daily newsletter.

ICEL Stock News Headlines

Erdemli, İçel, Türkiye
Why Elon Musk Is Investigating Fort Knox
With gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulate more of the precious metal, the timing couldn't be more critical. If the gold reserves in Fort Knox are found to be less than officially reported, we could see gold prices skyrocket virtually overnight.
Tarsus, İçel, Türkiye
See More Headlines

ICEL Stock Analysis - Frequently Asked Questions

(ICEL) (NASDAQ:ICEL) posted its quarterly earnings results on Thursday, March, 5th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.08. The business earned $6.60 million during the quarter, compared to analysts' expectations of $5 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that (ICEL) investors own include Bank of America (BAC), Bristol-Myers Squibb (BMY), Avid Bioservices (CDMO), Clovis Oncology (CLVS), Corcept Therapeutics (CORT), CRISPR Therapeutics (CRSP) and CTI BioPharma (CTIC).

Company Calendar

Last Earnings
3/05/2015
Today
4/02/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:ICEL
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (NASDAQ:ICEL) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners